Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease
Visa övriga samt affilieringar
Antal upphovsmän: 142019 (Engelska)Ingår i: Clinica Chimica Acta, ISSN 0009-8981, E-ISSN 1873-3492, Vol. 494, s. 79-93Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Detailed knowledge of protein changes in cerebrospinal fluid (CSF) across healthy and diseased individuals would provide a better understanding of the onset and progression of neurodegenerative disorders. In this study, we selected 20 brain-enriched proteins previously identified in CSF by antibody suspension bead arrays (SBA) to be potentially biomarkers for Alzheimer's disease (AD) and verified these using an orthogonal approach. We examined the same set of 94 CSF samples from patients affected by AD (including preclinical and prodromal), mild cognitive impairment (MCI), non-AD dementia and healthy individuals, which had previously been analyzed by SBA. Twenty-eight parallel reaction monitoring (PRM) assays were developed and 13 of them could be validated for protein quantification. Antibody profiles were verified by PRM. For seven proteins, the antibody profiles were highly correlated with the PRM results (r > 0.7) and GAP43, VCAM1 and PSAP were identified as potential markers of preclinical AD. In conclusion, we demonstrate the usefulness of targeted mass spectrometry as a tool for the orthogonal verification of antibody profiling data, suggesting that these complementary methods can be successfully applied for comprehensive exploration of CSF protein levels in neurodegenerative disorders.

Ort, förlag, år, upplaga, sidor
2019. Vol. 494, s. 79-93
Nyckelord [en]
Alzheimer's disease, AD, Biomarkers, Cerebrospinal fluid, Suspension bead array (SBA), Parallel reaction monitoring (PRM)
Nationell ämneskategori
Klinisk laboratoriemedicin Biomedicinsk laboratorievetenskap/teknologi
Identifikatorer
URN: urn:nbn:se:su:diva-170832DOI: 10.1016/j.cca.2019.03.243ISI: 000470950400013PubMedID: 30858094OAI: oai:DiVA.org:su-170832DiVA, id: diva2:1339333
Tillgänglig från: 2019-07-29 Skapad: 2019-07-29 Senast uppdaterad: 2019-07-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Kotol, DavidIlag, Leopold L.Nilsson, Peter
Av organisationen
Institutionen för miljövetenskap och analytisk kemi
I samma tidskrift
Clinica Chimica Acta
Klinisk laboratoriemedicinBiomedicinsk laboratorievetenskap/teknologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 85 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf